D. Lee

发表

Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study.

D. Heo, C. Suh, J. H. Lee, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small cell lung cancer.

A. Jimeno, A. Nagrial, D. Rasco, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer.

M. Ahn, E. Choi, S-H. Jung, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial of concurrent thoracic radiotherapy with either fi rst-or third-cycle chemotherapy for limited-disease small-cell lung cancer †

M. Ahn, E. Choi, S-H. Jung, 2013 .

Safety and Efficacy of Quavonlimab, a Novel Anti-CTLA-4 Antibody (MK-1308), in Combination with Pembrolizumab in First-Line Advanced Non-Small Cell Lung Cancer.

M. Ahn, A. Nagrial, M. Satouchi, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.

Dae-Ho Lee, C. Suh, H. T. Kim, 2012, Lung Cancer.

A phase II study of gefitinib as a dirst-line therapy of advanced or metastatic adenocarcinoma of the lung in lifetime non-smokers

D. Lee, E. Hong, Haesook T. Kim, 2005 .

A randomized open-label study of gefitinib versus docetaxel in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who have previously received platinum-based chemotherapy

C. Suh, J. Lee, M. Ahn, 2008 .

Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients.

H. Eom, C. Suh, S. S. Yoon, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer

J.-Y. Han, D. Lee, E. Hong, 2005, Journal of Clinical Pathology.

Safety and efficacy of pralsetinib in RET fusion-positive non-small cell lung cancer including as first-line therapy: update from the ARROW trial.

Y. Houvras, A. Mansfield, J. Mazières, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?

Y. Ko, J. Huh, C. Suh, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimal timing of G-CSF administration for effective autologous stem cell collection

J. Kim, C. Suh, D. Lee, 2011, Bone Marrow Transplantation.

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.

K. O'Byrne, T. Mok, E. Tan, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment.

D. Lee, S. Kim, J. Lee, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience

J. Huh, C. Suh, C. Suh, 2011, Bone Marrow Transplantation.

Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer

K. Park, S. Jang, R. Bayliss, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial

M. Schuler, D. Hong, A. Delmonte, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

K. O'Byrne, T. Mok, E. Tan, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II cross-over sequential chemotherapy trial of irinotecan/cisplatin (IP) vs. gemcitabine/vinorelbine (GV) in chemo-naïve patients with stage IIIb/IV non-small cell lung cancer (NSCLC).

J. Lee, D. Lee, H. Kim, 2006, Journal of Clinical Oncology.

1284P MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer

L. Sequist, L. Paz-Ares, D. Tan, 2020 .

Serum HER-2 concentration in patients with primary breast cancer

S. Kong, J. Ro, D. Lee, 2006, Journal of Clinical Pathology.

Small but powerful: Short peptide hormones and their role in autoimmune inflammation

R. Gold, R. Linker, D. Lee, 2009, Journal of Neuroimmunology.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Retaining ALK Rearrangement in Cultured Circulating Tumor Cells Derived from Lung Cancer Patients

Se-Hoon Lee, M. Kim, D. Lee, 2015 .

Updated results of M7824 (MSB0011359C): A bifunctional fusion protein targeting TGF-β and PD-L1, in second-line (2L) NSCLC.

L. Paz-Ares, B. Cho, M. Di Nicola, 2018, Annals of Oncology.

Pharmacogenetic prediction for tumor response, toxicity, and survival of NSCLC patients treated with irinotecan and cisplatin chemotherapy

H. Kim, Ji-Youn Han, S. Lee, 2007 .

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutations.

S. Jang, C. Suh, J. Lee, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase II ALTA trial

Edward S. Kim, H. Groen, S. Gettinger, 2019, Annals of Oncology.

A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study (vol 16, 153, 2016)

J. Bridgewater, H. Wasan, J. Valle, 2016 .

Corrigendum to 'Consensus for HER2 Alterations Testing in Non-small Cell Lung Cancer': [ESMO Open Volume 7 Issue 1 (2022) 100395].

T. Mitsudomi, J. Ying, Y. Shu, 2022, ESMO open.

Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC)

R. Doebele, G. Curigliano, S. Gadgeel, 2019, Annals of Oncology.